Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
10
×
boston top stories
life sciences
national blog main
new york blog main
10
×
national top stories
new york top stories
san diego blog main
biotech
clinical trials
san diego top stories
san francisco blog main
indiana blog main
raleigh-durham blog main
san francisco top stories
seattle blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana top stories
national
raleigh-durham top stories
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer
deals
fda
pfizer
alnylam pharmaceuticals
amgen
boston
gene therapy
medicare
merck
novartis
spark therapeutics
What
patients
10
×
drug
fda
bio
roundup
market
medicine
ago
alnylam
approved
disease
friday
gene
help
moves
new
pfizer
sets
therapy
acorda
acquisitions
advantages
akcea
albert
amyloidosis
approve
aren’t
attr
available
awaits
bar
battle
becker
benefiting
beta
biggest
billions
biological
bionics
blood
Language
unset
unknown
Current search:
patients
×
" boston blog main "
×
" new york blog main "
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision